FB4 (Framingham, Boston, Bloomington, Birmingham, and Baylor)
NCT ID: NCT03394664
Last Updated: 2021-06-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
166 participants
INTERVENTIONAL
2018-05-09
2020-05-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolic Fuels Study
NCT02235038
Experimental Approach to Test Predictions of Body Weight Regulation Models
NCT06309576
Framingham State Food Study
NCT02068885
Effect of Low Carbohydrate Versus Low Fat Diet in the Treatment of Dyslipidemia in Obese Children With Metabolic Syndrome
NCT03937960
Effect of a Carbohydrate-rich Diet in Healthy Subjects
NCT04088344
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To test this hypothesis, the investigators plan a randomized-controlled feeding study involving 125 adults with obesity. During the run-in phase, participants will be given a hypocaloric very-low-carbohydrate (VLC) diet, with adjustment of energy intake to produce 15 ± 3% weight loss over 3 to 4 months on an outpatient basis. After weight stabilization, participants will be admitted to a residential center for 13 weeks. During the first 3 weeks, energy intake and expenditure will be closely monitored during weight-loss maintenance. Then, energy intake will be individually "locked" at levels equal to energy expenditure and participants will be administered one of three randomly-assigned test diets for 10 weeks. The test diets include VLC, High Carbohydrate-Low Sugar (HC-LS), and High Carbohydrate-High Sugar (HC-HS).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Very-Low Carbohydrate Diet
Feeding study. Dietary composition (approximately): 75% fat
Feeding Study
Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
High-Carbohydrate Low-Sugar Diet
Feeding study. Dietary composition (approximately): 25% fat 0% added sugars.
Feeding Study
Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
High-Carbohydrate High-Sugar Diet
Feeding study. Dietary composition (approximately): 25% fat, 20% added sugars.
Feeding Study
Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Feeding Study
Food provision throughout the study: 1) Run-In Phase (VLC diet, weight loss); 2) Residential Phase (3 different test diets, weight-loss maintenance).
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI ≥ 27 kg/m2
* Weight ≤ 350 lb
* Medical clearance from a primary care provider
* Willingness to follow a VLC weight-loss diet
* Willingness to reside in a research unit for 3 months and eat/drink only provided study foods and beverages
* No major food allergies or aversions
* Willingness to obtain seasonal flu shot or provide documentation of flu shot for current flu season (winter/spring cohort only)
* Willingness to discuss work options (e.g., remote work) with employer, and make appropriate arrangements prior to the Residential phase.
Exclusion Criteria
* Specialized diets (e.g., for medical or religious reasons)
* Chronic use of any medication or dietary supplement that could affect study outcomes (e.g., insulin, metformin, thyroxine)
* Current smoking (1 cigarette in the last week)
* Greater than moderate alcohol consumption (\> 14 drinks/wk) or history of binge drinking (≥5 drinks in 1 day within past 6 months)
* Physician diagnosis of a major medical illness or eating disorder
* History of kidney stones
* Laboratory tests: ALT\>2x upper limit; abnormal HgA1c; abnormal TSH; abnormal creatinine; abnormal uric acid (using the male upper limit for both sexes)
* Failed criminal offender background check or sex offender background check
* Use of recreational drugs
* Current diagnosis or history of kidney stones, gout, or gall stones; or removal of gall bladder
* Exercise restrictions or at high risk for complications during exercise
* Menopausal
* Any change in birth control medication during the 3 months prior to enrollment
* Pregnancy or lactation during the 12 months prior to enrollment, or intent to become pregnant during study participation
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Indiana University
OTHER
University of Alabama at Birmingham
OTHER
Framingham State University
OTHER
Baylor University
OTHER
Boston Children's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
David S. Ludwig, MD, PhD
Co-Director, New Balance Foundation Obesity Prevention Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David S Ludwig, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Boston Children's Hospital
David B Allison, PhD
Role: PRINCIPAL_INVESTIGATOR
Indiana University, Bloomington
Cara B Ebbeling, PhD
Role: STUDY_DIRECTOR
Boston Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Warren Conference Center and Inn
Ashland, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Ludwig DS, Friedman MI. Increasing adiposity: consequence or cause of overeating? JAMA. 2014 Jun 4;311(21):2167-8. doi: 10.1001/jama.2014.4133. No abstract available.
Ebbeling CB, Swain JF, Feldman HA, Wong WW, Hachey DL, Garcia-Lago E, Ludwig DS. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA. 2012 Jun 27;307(24):2627-34. doi: 10.1001/jama.2012.6607.
Wong MC, Bennett JP, Leong LT, Tian IY, Liu YE, Kelly NN, McCarthy C, Wong JMW, Ebbeling CB, Ludwig DS, Irving BA, Scott MC, Stampley J, Davis B, Johannsen N, Matthews R, Vincellette C, Garber AK, Maskarinec G, Weiss E, Rood J, Varanoske AN, Pasiakos SM, Heymsfield SB, Shepherd JA. Monitoring body composition change for intervention studies with advancing 3D optical imaging technology in comparison to dual-energy X-ray absorptiometry. Am J Clin Nutr. 2023 Apr;117(4):802-813. doi: 10.1016/j.ajcnut.2023.02.006. Epub 2023 Feb 14.
Jansen LT, Yang N, Wong JMW, Mehta T, Allison DB, Ludwig DS, Ebbeling CB. Prolonged Glycemic Adaptation Following Transition From a Low- to High-Carbohydrate Diet: A Randomized Controlled Feeding Trial. Diabetes Care. 2022 Mar 1;45(3):576-584. doi: 10.2337/dc21-1970.
Wong JMW, Yu S, Ma C, Mehta T, Dickinson SL, Allison DB, Heymsfield SB, Ebbeling CB, Ludwig DS. Stimulated Insulin Secretion Predicts Changes in Body Composition Following Weight Loss in Adults with High BMI. J Nutr. 2022 Mar 3;152(3):655-662. doi: 10.1093/jn/nxab315.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB-P00026977
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.